RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients

RedHill Biopharma Ltd RDHL has announced topline results from the Phase 2 part of the Phase 2/3 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients.

  • The study showed promising efficacy results delivering a 100% reduction in hospitalization due to COVID-19, with zero patients on RHB-107 hospitalized with COVID-19 compared to 15% on the placebo-controlled arm requiring hospitalization. 
  • Furthermore, the study showed an 87.8% reduction in reported new severe COVID-19 symptoms, with only one patient on RHB-107 (2.4%, 1/41) compared to 20% (4/20) of patients on the placebo-controlled arm experiencing new COVID-19 related severe symptoms.
  • Also See: RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients.
  • The study met its primary outcome measure, demonstrating a favorable safety and tolerability profile of RHB-107.
  • RHB-107 is an orally-administered antiviral targeting human serine proteases that prepare the spike protein for viral entry into target cells. 
  • Price Action: RDHL shares are down 6.39% at $2.05 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!